What is Allena Pharmaceuticals, Inc. (ALNAQ) stock price today?

Allena Pharmaceuticals, Inc. (ALNAQ) is currently trading at $0.00.

What is ALNAQ return on equity (ROE)?

Allena Pharmaceuticals, Inc.'s return on equity (ROE) is -263.16%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Allena Pharmaceuticals, Inc.'s market cap?

Allena Pharmaceuticals, Inc. has a market capitalization of $122.

OTC · Biotechnology

Allena Pharmaceuticals, Inc. (ALNAQ) Stock

$0.00 OTC: ALNAQ Healthcare

Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies.

Valuation

Metric	Value
Price	$0.00
Market Cap	$122
P/E Ratio	—
P/B Ratio	0.00
P/S Ratio	—
EPS (TTM)	$-0.73
52-Week High	$6.00
52-Week Low	—
Dividend Yield	—

Financials & Margins

Metric	Value
ROE	-263.16%
ROA	-142.86%
ROCE	-252.63%
Gross Margin	—
Operating Margin	—
Net Margin	—
Debt/Equity	0.53
Current Ratio	2.06

Annual Financials (USD)

Metric	2017	2018	2019	2020	2021
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-21.0M	$-36.0M	$-46.0M	$-32.0M	$-48.0M
Net Profit	$-22.0M	$-36.0M	$-48.0M	$-33.0M	$-50.0M
EPS	$-1.05	$-1.72	$-2.15	$-1.01	$-0.73
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2017	2018	2019	2020	2021
Total Assets	$96.0M	$65.0M	$34.0M	$39.0M	$35.0M
Total Liabilities	$13.0M	$16.0M	$17.0M	$16.0M	$16.0M
Cash	$94.0M	$62.0M	$30.0M	$35.0M	$30.0M
Borrowings	$9.0M	$10.0M	$10.0M	$11.0M	$10.0M

Latest News

South Korea says the chance of 3% economic growth has risen sharply Reuters · Aug 6, 2026 Walmart's bestselling 5-tier adjustable shelf that holds up to 750 pounds is on sale for $34 TheStreet · Aug 6, 2026 Dow Jones Futures: Nvidia Lifts Dow, But Google, SpaceX Skid; Sandisk, Western Digital Lead Earnings Losers Late Investor's Business Daily · Aug 6, 2026 BAM (BAM) Q2 2026 Earnings Call Transcript Motley Fool · Aug 6, 2026 Mike Lindell steps down as MyPillow CEO to focus on Minnesota campaign USA TODAY · Aug 6, 2026

Cash Flow (USD)

Metric	2017	2018	2019	2020	2021
Operating Cash Flow	$-21.0M	$-32.0M	$-44.0M	$-28.0M	$-46.0M
Investing Cash Flow	$23.0M	$-1.0M	$0	$-1.0M	$-1.0M
Financing Cash Flow	$67.0M	$9.0M	$12.0M	$34.0M	$41.0M
Net Cash Flow	$69.0M	$-33.0M	$-32.0M	$5.0M	$-5.0M
Free Cash Flow	$-21.0M	$-32.0M	$-44.0M	$-29.0M	$-46.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-37704918.03%
Quick Ratio	2.06
Interest Coverage	—
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BUGVFPrimo Nutraceuticals Inc.	$0.00	—	0.00	$26	0.00%
GRYNGreen Hygienics Holdings Inc.	$0.00	—	0.00	$44	0.00%
IMVIQIMV Inc.	$0.00	—	-0.18	$117	0.00%
INDRIndie Ranch Media, Inc.	$0.00	—	—	$132	0.00%
LHRPLifeHOUSE Holdings, LLC	$0.00	—	—	$34	0.00%

About Allena Pharmaceuticals, Inc.

Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies. These treatments are devised to assist patients in the United States afflicted by uncommon and serious metabolic as well as renal conditions. Central to its pipeline is ALLN-346, an innovative enzyme designed to degrade urate, targeting hyperuricemia and gout in individuals with advanced chronic kidney disease. The company, which commenced operations in 2011 and has its main office in Newton, Massachusetts, made headlines on September 2, 2022, by seeking voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Allena Pharmaceuticals, Inc. (ALNAQ) stock trades at $0.00 with a market capitalization of $122. The stock is valued at price-to-book of 0.00.

On profitability, Allena Pharmaceuticals, Inc. generates a return on equity (ROE) of -263.16%, return on capital employed of -252.63%.

Official website: www.allenapharma.com